ICE Bioscience Webinars

Qing is an International Project Manager at ICE Bioscience, where he leads the development of ICE Bioscience’s Induced Proximity platform, focusing on emerging modalities including RIPTAC, PROTAC, and molecular glue technologies. He has extensive experience in developing biochemical, cellular, DMPK, and in vivo assays to support proximity-based drug discovery programs. Qing holds a Ph.D. in Biology from Tsinghua University and a Master by Research in Biomedical Sciences from the University of Glasgow, with a strong background in targeted protein degradation and molecular biology.

Andrew Zhang is currently the Director of Pharma/Biotech Market Segment at Promega. Prior to joining Promega in 2024, he spent 11 years at AstraZeneca R&D, where he was most recently the Head of Chemical Biology. Over the course of the 11 years at AstraZeneca, Andrew gained experience in cellular target engagement assays, including target deconvolution with mass spectrometry based proteomics. His area of expertise is in the new modes of action being pursued, including targeted protein degradation, induced proximity, and covalent drug discovery. Andrew trained for his PhD at Yale University working at the interface of small molecules and biologics, investigating how to redirect immune response to pathogenic cells, and performed postdoctoral training at the Ontario Institute for Cancer Research in Toronto working on ADCs.